Radcliffe Capital Management, L.P. Sab Biotherapeutics, Inc. Transaction History

Radcliffe Capital Management, L.P.

  • $1.98 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.78 - $8.5 $973,051 - $4.65 Million
-546,658 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$7.3 - $11.24 $3.99 Million - $6.14 Million
546,658 New
546,658 $5.52 Million

Others Institutions Holding SABS

# of Institutions
3
Shares Held
529K
Call Options Held
0
Put Options Held
0
View Full List

About SAB Biotherapeutics, Inc.

SABS Quotes by TradingView
  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $172M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track Radcliffe Capital Management, L.P. Portfolio

Follow Radcliffe Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Radcliffe Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Radcliffe Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email